RNAdjuvant®, a novel, highly-potent RNA-based adjuvant, combines strong immunostimulatory capacities with a favorable safety profile

Autor:	Patrick Baumhof, Tilmann Roos, Angelika Daehling, Karl-Josef Kallen, Regina Heidenreich, Birgit Scheel, Henoch S. Hong, Aleksandra Kowalczyk, Karl Melber, Mariola Fotin-Mleczek, Söhnke Voss, Keyvan Tadjalli Mehr, Sven D. Koch, Ulrike Gnad-Vogt, Johannes Lutz, Janine Noth
Rok vydání:	2015
Předmět:	Pharmacology Cancer Research business.industry medicine.medical_treatment Immunogenicity Immunology RNA law.invention Vaccination Safety profile Oncology law Immunity Poster Presentation Cancer research Recombinant DNA Molecular Medicine Immunology and Allergy Medicine business Adjuvant
Zdroj:	Journal for Immunotherapy of Cancer
ISSN:	2051-1426
DOI:	10.1186/2051-1426-3-s2-p163
Popis:	Meeting abstracts Purified recombinant proteins and peptides, which are currently under development in various anti-cancer vaccination approaches, lack sufficient immunogenicity. Therefore, potent adjuvants are needed to induce strong and persistent anti-tumor immunity. However, currently only few
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c861f2e62319dc2d4d8417d86e1a81f https://doi.org/10.1186/2051-1426-3-s2-p163 Zobrazit plný text záznamu Full text from SpringerLink